Stay updated on M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.

Latest updates to the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdministrative updates to the history page include a new Revision: v3.3.3 and the removal of HHS Vulnerability Disclosure and Revision: v3.3.2, which do not affect study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision history shows a new version v3.3.2 was added and an older version v3.2.0 was removed, with no changes to the study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedRemoval of the general government funding operating-status notice from the page. This banner change does not alter the trial data or record contents. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check59 days agoChange DetectedRecord history now includes additional versions with updates to Study Status and Recruitment Status, and revisions to Contacts/Locations. These changes provide a more current view of the trial's activity and locations.SummaryDifference0.1%

- Check88 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference10%

- Check95 days agoChange DetectedChanged the revision tag from v3.0.2 to v3.1.0, updating the page's version/reference metadata.SummaryDifference0.2%

Stay in the know with updates to M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.